利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.016 秒)

    Recombinantly Modified Plasmin
    4.
    发明申请
    Recombinantly Modified Plasmin 有权
    重组改良的纤溶酶

    公开(公告)号：US20100304465A1

    公开(公告)日：2010-12-02

    申请号：US11568023

    申请日：2005-04-21

    申请人： Jennifer A. Hunt ,  Valery Novokhatny

    发明人： Jennifer A. Hunt ,  Valery Novokhatny

    IPC分类号： C12N9/50 ,  C07H21/04 ,  C12N15/63 ,  C12N1/00

    CPC分类号： C12N9/6435 ,  C12Y304/21007

    摘要： Polynucleotides and polypeptides relating to a recombinantly-modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, and exhibits lysine-binding and significant enzymatic characteristics associated with the native enzyme.

    摘要翻译： 提供了与重组修饰的纤溶酶（原）分子相关的多核苷酸和多肽。 纤溶酶原（Ogen）分子在天然人纤溶酶原分子中存在活化位点的N-末端单个三环结构域，并显示与天然酶相关的赖氨酸结合和显着的酶特征。

    METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR
    5.
    发明申请
    METHOD OF PREPARING ALPHA-1 PROTEINASE INHIBITOR 审中-公开
    制备ALPHA-1蛋白酶抑制剂的方法

    公开(公告)号：US20110237781A1

    公开(公告)日：2011-09-29

    申请号：US13002429

    申请日：2009-07-17

    申请人： Wytold Lebing ,  Scott A. Cook ,  Christopher A. Dadd

    发明人： Wytold Lebing ,  Scott A. Cook ,  Christopher A. Dadd

    IPC分类号： C07K1/36

    CPC分类号： C07K14/8125

    摘要： Purification of α-1 proteinase inhibitor (α-1 PI) from solutions comprising α-1 PI is accomplished using hydrophobic interaction chromatography (HIC). In some embodiments, purification of α-1 PI is accomplished by precipitation of contaminating proteins from a starting solution comprising α-1 PI, such as human plasma, followed by anion exchange resin chromatography prior to HIC. Further purification may be accomplished by an optional cation exchange chromatography subsequent to anion exchange chromatography but prior to HIC. Some embodiments of the invention also include virus removal and/or inactivation by methods such as nano filtration and such as contact with a non-ionic detergent. The methods of the present invention result in greater yield, purity, and pathogenic clearance of plasma fractions than known methods.

    摘要翻译： 使用疏水相互作用色谱（HIC）实现从包含α-1 PI的溶液中纯化α-1蛋白酶抑制剂（α-1 PI）。 在一些实施方案中，通过从包含α-1PI的起始溶液（例如人血浆）中沉淀污染性蛋白，然后在HIC之前进行阴离子交换树脂色谱来完成α-1 PI的纯化。 进一步纯化可以通过阴离子交换层析之后但在HIC之前的任选的阳离子交换层析来完成。 本发明的一些实施方案还包括通过诸如纳米过滤的方法和诸如与非离子型洗涤剂接触的病毒去除和/或灭活。 与已知方法相比，本发明的方法产生更高的产量，纯度和血浆级分的致病性清除。

    METHOD FOR ADJUSTING RESULTS OF A POLYMERASE CHAIN REACTION (PCR) INSTRUMENT
    7.
    发明申请
    METHOD FOR ADJUSTING RESULTS OF A POLYMERASE CHAIN REACTION (PCR) INSTRUMENT 有权
    调整聚合酶链反应（PCR）仪器结果的方法

    公开(公告)号：US20110004411A1

    公开(公告)日：2011-01-06

    申请号：US12742801

    申请日：2008-11-11

    申请人： Justin M. Paul ,  Burton D. Beames

    发明人： Justin M. Paul ,  Burton D. Beames

    IPC分类号： G06F19/00 ,  C12Q1/68

    CPC分类号： C12Q1/6851 ,  C12Q1/686 ,  C12Q2537/165 ,  C12Q2561/113

    摘要： Methods of managing results of a real-time polymerase chain reaction (PCR) instrument and software associated with such methods are described herein. One disclosed method, among others, comprises calculating, from results of the real-time PCR instrument, a fluorescence signal of a sample during a cycle of a baseline period of the real-time PCR instrument. The method further comprises determining whether or not the fluorescence signal during the baseline period increases by at least a certain percentage compared to cycles outside the baseline period. The sample is flagged as a potentially high-titer sample when the fluorescence signal increases by at least the certain percentage.

    摘要翻译： 本文描述了管理实时聚合酶链式反应（PCR）仪器和与这些方法相关的软件的结果的方法。 一种公开的方法，其中包括从实时PCR仪器的结果计算在实时PCR仪器的基线周期的循环期间样品的荧光信号。 该方法还包括确定基线期间内的荧光信号是否与基线周期之外的周期相比增加至少一定百分比。 当荧光信号增加至少一定百分比时，样品被标记为潜在的高滴度样品。

    Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
    9.
    发明授权
    Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin 有权
    通过局部递送可逆灭活的酸化纤溶酶进行溶栓治疗的方法

    公开(公告)号：US06969515B2

    公开(公告)日：2005-11-29

    申请号：US10280444

    申请日：2002-10-25

    申请人： Gary J. Jesmok ,  Kyle A. Landskroner

    发明人： Gary J. Jesmok ,  Kyle A. Landskroner

    IPC分类号： A61K20060101 ,  A61K38/00 ,  A61K38/48 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  A61K47/26 ,  C12N9/68

    CPC分类号： C12N9/6435 ,  A61K9/0019 ,  A61K38/4833 ,  A61K38/484 ,  A61K47/02 ,  A61K47/12 ,  A61K47/183 ,  A61K47/26 ,  C12Y304/21007

    摘要： Methods of thrombolysis that allow the use of a fibrinolytic composition comprising reversibly inactivated acidified plasmin and the localized delivery of the plasmin to a vascular thrombotic occlusion are disclosed. Further disclosed is a method for administering a therapeutic dose of a fibrinolytic composition substantially free of plasminogen activator to a human or animal having a vascular thrombotic occlusion. The fibrinolytic composition includes a reversibly inactivated acidified plasmin substantially free of plasminogen activator. Intravascular catheter delivery of the fibrinolytic composition directly into or in the immediate vicinity of the thrombus is disclosed to minimize the systemic degradation of fibrin while retaining the maximum plasmin activity against the thrombus. The method is applicable to the dissolution of thrombi in artificial devices, e.g., hemodialysis grafts.

    摘要翻译： 公开了允许使用包含可逆灭活的酸化纤溶酶的纤维蛋白溶解组合物以及将纤溶酶局限性递送至血管性血栓闭塞的溶栓方法。 进一步公开的是一种治疗剂量的基本上不含纤溶酶原激活剂的纤维蛋白溶解组合物给予具有血管性血栓闭塞的人或动物的方法。 纤维蛋白溶解组合物包括基本上不含纤溶酶原激活物的可逆失活的酸化纤溶酶。 公开了将纤维蛋白溶解组合物直接进入或紧邻血栓的血管内导管递送，以使纤维蛋白的全身降解最小化，同时保留针对血栓的最大纤溶酶活性。 该方法适用于血栓在人造装置中的溶解，例如血液透析移植物。